Last close As at 05/08/2026
EUR34.24
▲ −0.56 (−1.61%)
Market capitalisation
EUR2,693m
Research: Industrials
Theon is a market leader in night vision and thermal imaging systems. The group has released a positive update on FY24 and further order intake for Q4, providing momentum into FY25. The latest events in the Middle East are likely to support military budgets globally. This will provide a positive environment for Theon that will be supplemented by internal development to expand the product portfolio to support integrated battlefield requirements.
Theon International |
Positive update on FY24 |
Business update |
Aerospace and defence |
9 December 2024 |
Share price performance
Business description
Analyst
Theon is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||
Theon is a market leader in night vision and thermal imaging systems. The group has released a positive update on FY24 and further order intake for Q4, providing momentum into FY25. The latest events in the Middle East are likely to support military budgets globally. This will provide a positive environment for Theon that will be supplemented by internal development to expand the product portfolio to support integrated battlefield requirements.
Year end |
Revenue (€m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/22 |
143 |
38 |
N/A |
0 |
N/A |
N/A |
12/23 |
219 |
50 |
N/A |
0 |
N/A |
N/A |
12/24e |
339 |
83 |
93 |
31 |
14.1 |
2.6 |
12/25e |
382 |
96 |
104 |
35 |
12.2 |
3.0 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Theon has announced two additional orders amounting to €47m for monocular Argus, Theon’s binocular NYX, and its thermal imaging clip-on system IRIS-C. Of particular note is the thermal imaging components, alongside the group’s traditional night vision systems, which form part of the company’s Augmented Reality Modular Ecosystem of Devices (A.R.M.E.D) strategy to service the developing integrated soldier requirements. These orders come after the update on 20 November, which announced Q4 orders of over €150m.
Management has provided updated guidance for FY24 with revenues at the top end of the previous range of €340–350m and operating margins in the mid-20s. This suggests FY24 will be at least in line with our current forecasts (sales €339m and operating margins of 24%). Looking forward, the CFO commented that Theon ‘will be able to provide equally positive guidance for FY25 in the coming weeks’. We will review our forecasts when this guidance is released.
|
|
Research: Investment Companies
Worldwide Healthcare Trust (WWH) will be celebrating its 30th birthday in 2025 and, despite more recent underperformance, the trust has served its shareholders well over the long term. Its NAV and share price total returns of +4,770% and +4,181% respectively, since launch in April 1995 to the end of September 2024, are considerably ahead of the benchmark’s +2,438% total return. Co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, remain bullish on the industry outlook. They believe that the sector is poised for a catch-up in relative performance, having uncharacteristically lagged the performance of the broad US market in recent quarters. The managers point to favourable healthcare industry fundamentals, which include a high level of innovation, a supportive regulatory environment and robust levels of M&A activity. This is partly due to an upcoming patent cliff and senior executives at major pharma companies have been vocal about the need to replenish their product lines as their key drugs go off patent.